🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

New York maps coronavirus genome to help track future outbreaks

Published 04/29/2020, 11:13 AM
Updated 04/29/2020, 11:32 AM
© Reuters. Scientists work in a lab testing COVID-19 samples at New York City's health department, during the outbreak of the coronavirus disease (COVID-19) in New York
LH
-

By Hussein Waaile and Jonathan Allen

NEW YORK (Reuters) - Scientists at New York City's health department have begun to analyze the novel coronavirus's genetic material to allow them to trace the origins of any future outbreaks in the coming months as they cautiously look to reopen the largely shuttered city.

Their work joins similar efforts at scores of institutions around the world, which have been sequencing the genomes of virus samples and pooling their findings in an online global database, allowing researchers to observe subtle differences between samples to track the outbreak's spread.

Dr. Oxiris Barbot, the city's health commissioner, told Reuters during a tour this week of the Public Health Laboratory (NYSE:LH) in Manhattan that genome sequencing could help blunt any second wave of infections later in the year.

"We can use that fingerprint information to understand if those additional infections are due to infections that were still here in the city or if they've been imported from someplace else," she said in an interview, wearing a floral-patterned cloth mask over her nose and mouth.

On the laboratory's ninth floor, scientists in blue protective gear and face shields are working on the sequencing in cramped rooms, the doors to which are plastered with hazard warnings and rules on safety precautions.

Colleagues on other floors run diagnostic tests for COVID-19, the potentially lethal respiratory illness caused by the coronavirus, on samples sent over from city hospitals without their own testing facilities.

Showerheads are embedded in the ceilings of the building's drab corridors, and can be activated with the yank of a cord if a worker fears they have been contaminated by whatever they are studying.

The genome of the novel coronavirus consists of a single, short strand of ribonucleic acid, or RNA, a distinctive sequence of genetic base molecules, sometimes described by letters, that the virus uses to hijack its host's cellular machinery and make copies of itself.

Only four different kinds of letters make up a string of RNA, referred to by geneticists as c, u, a and g. The novel coronavirus genome is about 30,000 letters long, tiny compared with the 3 billion letters that make up the DNA, or deoxyribonucleic acid, of the human genome.

As the virus replicates itself inside its host, it can make tiny transcription errors, altering its genetic signature. These mutations, which can be passed along in subsequent infections, can be detected in samples taken from patients to create a sort of genetic family tree.

Across First Avenue from the Public Health Laboratory, scientists at New York University's Grossman School of Medicine who sequenced samples of the virus deduced that the variant of the virus dominating in New York City - the heart of one the deadliest outbreaks in the world - arrived via Europe.

"It's sort of like doing detective work," Adriana Heguy, one of the New York University researchers, said in an interview.

She has been sharing her results with colleagues around the world via the Germany-based GISAID database, which was created to track the ebb and flow of influenza viruses. "You can find your chain of transmission by doing this," she said.

Health officials can use this knowledge to determine which measures are more effective than others and where their points of vulnerability may lie.

© Reuters. Scientists work in a lab testing COVID-19 samples at New York City's health department, during the outbreak of the coronavirus disease (COVID-19) in New York

While most mutations are trivial and do not affect the virus's behavior, Heguy and other researchers are also working to amass enough samples to see if there are any clinical differences seen in different variants of the virus, and their work may help design a vaccine that offers the broadest possible protection.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.